Clinical trial / 2008
In humans, serum FGF21 varied widely and increased after 7 days of fasting and fenofibrate treatment, but not after a 2-day fast or ketogenic diet.
Researchers investigated the physiological regulation of circulating FGF21 in humans. Serum FGF21 varied 250-fold among 76 healthy individuals and did not relate to age, gender, BMI, serum lipids, or plasma glucose, with no diurnal variation. Ketosis from a 2-day fast or ketogenic diet did not alter FGF21 levels, but a 74% increase occurred after 7 days of fasting. Hypertriglyceridemic nondiabetic patients had 2-fold higher FGF21 levels, which increased an additional 28% during fenofibrate treatment.
- Study type
- Interventional and observational human study
- Who was studied
- 76 healthy individuals alongside hypertriglyceridemic nondiabetic patients
- What was measured
- Serum FGF21 levels under varying conditions (fasting, ketogenic diet, fenofibrate)
THE PAPER
The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man.
Gälman C, Lundåsen T, Kharitonenkov A, Bina HA, Eriksson M, Hafström I, Dahlin M, Amark P, Angelin B, Rudling M. Cell Metab, 2008.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.